606 related articles for article (PubMed ID: 27222326)
1. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.
Gong X; Yin H; Shi Y; He X; Yu Y; Guan S; Kuai Z; Haji NM; Haji NM; Kong W; Shan Y
Emerg Microbes Infect; 2016 May; 5(5):e51. PubMed ID: 27222326
[TBL] [Abstract][Full Text] [Related]
2. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
[TBL] [Abstract][Full Text] [Related]
3. Protective immunity against influenza virus challenge by norovirus P particle-M2e and HA2-AtCYN vaccines in chickens.
Elaish M; Xia M; Ngunjiri JM; Ghorbani A; Jang H; Kc M; Abundo MC; Dhakal S; Gourapura R; Jiang X; Lee CW
Vaccine; 2019 Oct; 37(43):6454-6462. PubMed ID: 31506195
[TBL] [Abstract][Full Text] [Related]
4. Protective Efficacy of Recombinant Influenza Hemagglutinin Ectodomain Fusions.
Mittal N; Sengupta N; Malladi SK; Reddy P; Bhat M; Rajmani RS; Sedeyn K; Saelens X; Dutta S; Varadarajan R
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578291
[TBL] [Abstract][Full Text] [Related]
5. Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection.
Gocník M; Fislová T; Mucha V; Sládková T; Russ G; Kostolanský F; Varečková E
J Gen Virol; 2008 Apr; 89(Pt 4):958-967. PubMed ID: 18343837
[TBL] [Abstract][Full Text] [Related]
6. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response.
Lee JS; Chowdhury MY; Moon HJ; Choi YK; Talactac MR; Kim JH; Park ME; Son HY; Shin KS; Kim CJ
J Virol Methods; 2013 Dec; 194(1-2):280-8. PubMed ID: 24004822
[TBL] [Abstract][Full Text] [Related]
7. Heterosubtypic protection against influenza A induced by adenylate cyclase toxoids delivering conserved HA2 subunit of hemagglutinin.
Staneková Z; Adkins I; Kosová M; Janulíková J; Sebo P; Varečková E
Antiviral Res; 2013 Jan; 97(1):24-35. PubMed ID: 23036818
[TBL] [Abstract][Full Text] [Related]
8. An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.
Abdoli A; Soleimanjahi H; Tavassoti Kheiri M; Jamali A; Mazaheri V; Abdollahpour Alitappeh M
Pathog Dis; 2014 Dec; 72(3):197-207. PubMed ID: 25066138
[TBL] [Abstract][Full Text] [Related]
9. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119
[TBL] [Abstract][Full Text] [Related]
10. Broadly Protective CD8
Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
J Virol; 2021 May; 95(12):. PubMed ID: 33827939
[TBL] [Abstract][Full Text] [Related]
11. Conserved stem fragment from H3 influenza hemagglutinin elicits cross-clade neutralizing antibodies through stalk-targeted blocking of conformational change during membrane fusion.
Gong X; Yin H; Shi Y; Guan S; He X; Yang L; Yu Y; Kuai Z; Jiang C; Kong W; Wang S; Shan Y
Immunol Lett; 2016 Apr; 172():11-20. PubMed ID: 26875772
[TBL] [Abstract][Full Text] [Related]
12. Alternative Strategy for a Quadrivalent Live Attenuated Influenza Virus Vaccine.
Wan Z; Cardenas Garcia S; Liu J; Santos J; Carnaccini S; Geiger G; Ferreri L; Rajao D; Perez DR
J Virol; 2018 Nov; 92(21):. PubMed ID: 30135124
[TBL] [Abstract][Full Text] [Related]
13. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
J Virol; 2017 May; 91(9):. PubMed ID: 28179535
[TBL] [Abstract][Full Text] [Related]
14. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
[TBL] [Abstract][Full Text] [Related]
15. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.
Khurana S; Loving CL; Manischewitz J; King LR; Gauger PC; Henningson J; Vincent AL; Golding H
Sci Transl Med; 2013 Aug; 5(200):200ra114. PubMed ID: 23986398
[TBL] [Abstract][Full Text] [Related]
16. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein.
Staneková Z; Király J; Stropkovská A; Mikušková T; Mucha V; Kostolanský F; Varečková E
Acta Virol; 2011; 55(1):61-7. PubMed ID: 21434706
[TBL] [Abstract][Full Text] [Related]
17. Protective Immunity Against Homologous and Heterologous Influenza Virus Lethal Challenge by Immunization with New Recombinant Chimeric HA2-M2e Fusion Protein in BALB/C Mice.
Ameghi A; Pilehvar-Soltanahmadi Y; Baradaran B; Barzegar A; Taghizadeh M; Zarghami N; Aghaiypour K
Viral Immunol; 2016 May; 29(4):228-34. PubMed ID: 27058011
[TBL] [Abstract][Full Text] [Related]
18. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
[TBL] [Abstract][Full Text] [Related]
19. Protection of guinea pigs by vaccination with a recombinant swinepox virus co-expressing HA1 genes of swine H1N1 and H3N2 influenza viruses.
Xu J; Yang D; Huang D; Xu J; Liu S; Lin H; Zhu H; Liu B; Lu C
Arch Virol; 2013 Mar; 158(3):629-37. PubMed ID: 23135159
[TBL] [Abstract][Full Text] [Related]
20. Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.
Tsybalova LM; Stepanova LA; Shuklina MA; Mardanova ES; Kotlyarov RY; Potapchuk MV; Petrov SA; Blokhina EA; Ravin NV
PLoS One; 2018; 13(8):e0201429. PubMed ID: 30138320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
